Loading…
Cullinan Therapeutics, Inc. is projected to rise to $20.92 by 2027, a +27% move from its current price of $16.50. CGEM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $16.00 | $16.51 | $17.03 | +0.05% |
| Aug 3 | $15.81 | $16.52 | $17.26 | +0.11% |
| Aug 4 | $15.66 | $16.53 | $17.44 | +0.16% |
| Aug 5 | $15.54 | $16.53 | $17.59 | +0.21% |
| Aug 6 | $15.44 | $16.54 | $17.73 | +0.26% |
| Aug 7 | $15.34 | $16.55 | $17.86 | +0.32% |
| Aug 8 | $15.26 | $16.56 | $17.98 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.26 | $16.56 | $17.98 | +0.37% |
| Week 2 | $14.80 | $16.62 | $18.67 | +0.74% |
| Week 3 | $14.48 | $16.68 | $19.23 | +1.12% |
| Week 4 | $14.21 | $16.75 | $19.73 | +1.49% |
| Week 5 | $13.99 | $16.81 | $20.19 | +1.87% |
| Week 6 | $13.80 | $16.87 | $20.62 | +2.25% |
| Week 7 | $13.63 | $16.93 | $21.04 | +2.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on therapies for autoimmune diseases and cancer in the United States. It develops CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell engager in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc.
and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Therapeutics, Inc. (CGEM) is a healthcare company currently priced at $17.28 with a market capitalization of $1.06B. It holds a position in the market with a rank of 2450.
The stock’s price outlook, based on the distribution of forecasts, indicates a trajectory toward higher values over the coming years, with multi-year averages progressing from the 2026 level toward substantially higher targets by 2050.
A major floor 27.0% below — a decisive break under it would weaken the trend.
The nearest floor, 8.9% below — buyers have tended to step in here.
The nearest ceiling, 12.0% above — a clean break opens room to run.
A major ceiling 21.9% above — clearing it would confirm fresh momentum.
Key CGEM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGEM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.23 | Sell | $17.11 | Sell |
| MA 10 | $17.37 | Sell | $17.28 | Sell |
| MA 20 | $17.61 | Sell | $17.28 | Sell |
| MA 50 | $16.30 | Buy | $16.55 | Sell |
| MA 100 | $15.26 | Buy | $15.39 | Buy |
| MA 200 | $13.05 | Buy | $13.74 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.44 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -181.82 | Sell |
| Williams %R (14) | -94.55 | Info |
| MACD (12,26,9) | -0.19 | Sell |
| ROC (12) | -7.46 | Sell |
| Bollinger %B (20,2) | -0.03 | Buy |
| Stochastic %K (14) | 5.45 | Buy |
| TRIX (15) | 0.32 | Buy |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 33.39 | Neutral |
| Momentum (10) | -1.19 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 17.11 | Sell |
| ADX (14) | 13.59 | Neutral |
| ATR (14) | 0.44 | Info |
The 30-day technical picture remains mixed but has bullish undertones. RSI14 is 50, signaling neutral momentum near the midpoint. The stock trades against moving averages with SMA50 at $16.10 and SMA200 at $12.74, suggesting a constructive trend above longer-term support levels.
The key near-term support is $12.05, with resistance at $18.48. The 30-day price range runs from $13.85 to $21.57, indicating a broad trading channel over the last month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.99 | $16.50 | $21.88 | 0% | Neutral | |
| $16.48 | $20.92 | $28.20 | +27% | Bullish | |
| $22.16 | $29.06 | $40.84 | +76% | Bullish | |
| $22.73 | $30.63 | $44.47 | +86% | Bullish | |
| $23.53 | $32.46 | $48.43 | +97% | Bullish | |
| $25.06 | $35.34 | $53.99 | +114% | Bullish | |
| $24.68 | $35.51 | $55.40 | +115% | Bullish | |
| $31.31 | $45.92 | $73.02 | +178% | Bullish | |
| $36.95 | $55.18 | $89.30 | +234% | Bullish | |
| $36.56 | $55.56 | $91.39 | +237% | Bullish | |
| $55.10 | $90.68 | $159.56 | +450% | Bullish | |
| $79.55 | $150.50 | $292.03 | +812% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.99 | $16.50 | $19.97 | +0.00% |
| September 2026 | $13.92 | $16.53 | $20.24 | +0.19% |
| October 2026 | $14.47 | $17.32 | $21.46 | +4.74% |
| November 2026 | $14.74 | $17.75 | $22.21 | +2.52% |
| December 2026 | $14.31 | $17.33 | $21.88 | -2.36% |
Click any year to see its month-by-month CGEM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cullinan Therapeutics, Inc.'s 2026 outlook centres on $16.50, within a $9.99 to $21.88 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CGEM could reach as high as $28.20, with a base case around $20.92 and support toward $16.48 — roughly +27% from $16.50. Momentum favours further upside here.
Expect CGEM to range from $22.16 to $40.84 through 2028. The $29.06 average target implies a +76% move from current prices. That is up +39% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CGEM price prediction for 2029 points to an average of $30.63 (low $22.73, high $44.47) — a potential gain of +86% on today's $16.50. Momentum favours further upside here.
In 2030, CGEM is projected to trade between $23.53 and $48.43, averaging $32.46 — a potential gain of +97% from today's $16.50. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cullinan Therapeutics, Inc.'s 2031 outlook centres on $35.34, within a $25.06 to $53.99 range. That is up +9% on the projected 2030 average. That marks a +114% change versus current levels. Momentum favours further upside here.
By 2032, CGEM could reach as high as $55.40, with a base case around $35.51 and support toward $24.68 — roughly +115% from $16.50. Buyers look set to stay in control over this stretch.
Expect CGEM to range from $31.31 to $73.02 through 2033. The $45.92 average target implies a +178% move from current prices. That is up +29% on the projected 2032 average. Momentum favours further upside here.
The CGEM price prediction for 2034 points to an average of $55.18 (low $36.95, high $89.30) — a potential gain of +234% on today's $16.50. Buyers look set to stay in control over this stretch.
In 2035, CGEM is projected to trade between $36.56 and $91.39, averaging $55.56 — a potential gain of +237% from today's $16.50. That is up +1% on the projected 2034 average. Momentum favours further upside here.
Cullinan Therapeutics, Inc.'s 2040 outlook centres on $90.68, within a $55.10 to $159.56 range. That is up +63% on the projected 2035 average. That marks a +450% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CGEM could reach as high as $292.03, with a base case around $150.50 and support toward $79.55 — roughly +812% from $16.50. Momentum favours further upside here.
Investing $1,000 in CGEM today (≈ 60.606061 CGEM) could be worth
$9,121.07
+$8,121.07 (+812%) by 2050 · US Dollar
Based on the average projected CGEM price of $150.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGEMwould be worth at today's price.
$1,000 invested in CGEM on Jul 31, 2025 (≈ 128.700129 CGEM) would be worth
$2,123.55
+$1,123.55 (+112.4%) today · 2.12× · US Dollar
Based on a CGEM entry price of $7.77 vs. today's $16.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.1 | $964.91 | -3.5% |
| 1 month ago | $17.28 | $954.86 | -4.5% |
| 3 months ago | $13.43 | $1,228.59 | +22.9% |
| 6 months ago | $12.71 | $1,298.19 | +29.8% |
| 1 year ago | $7.77 | $2,123.55 | +112.4% |
| All time (5.0y) ago | $24.16 | $682.95 | -31.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGEM forecast.
Our base-case forecast reaches $33.00 around 2031.
Implied market cap at $33.00: $2.03B
The long-range forecast shows meaningful upside across the horizon. In 2026 the expected range is from a min of $9.99 to a max of $23.04, with an average of $17.28 and an ROI of 0%. The 2027 forecast projects a min of $17.55, an avg of $22.50, and a max of $30.73, with a 30.2% ROI and bullish sentiment.
The pattern continues with 2028 at a min of $23.58, avg $31.32, max $44.71 and an 81.2% ROI, still bullish, followed by 2029 with a min of $23.88, avg $32.67, max $48.28 and an 89% ROI. By 2030 the forecast shows a min of $24.77, avg $34.79, max $52.91 and a 101.3% ROI, with bullish sentiment. The longer-horizon years maintain a bullish stance, culminating in 2040 with an avg of $98.70, max $178.75 and a 471.2% ROI, and 2050 with an avg of $161.14, max $323.40 and an 832.5% ROI.
These figures imply substantial upside potential over time, but they are estimates and not guarantees, with risk factors inherent in pharmaceutical development and market conditions.
Tap a question to reveal the answer.
In 2030 the forecast shows min $24.77, avg $34.79, max $52.91, with ROI 101.3% and bullish sentiment.
The forecast shows bullish sentiment in 2027, 2028, 2029, 2030 onward, with 2026 neutral. The long-range outlook offers substantial upside through 2050 (e.g., avg $161.14, max $323.40 in 2050; ROI 832.5%), but these are estimates, not guarantees.
Yes. The 2050 forecast lists a max of $323.40, with an avg of $161.14, implying potential above $100 under the model’s projections.
Current price is $17.28 and market cap is $1.06B.
The 2040 forecast shows avg $98.70, max $178.75, min $57.75, with ROI 471.2% and bullish sentiment.
Cullinan Therapeutics, Inc. Community Discussion
0Share your Cullinan Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.